GeneDx Holdings Corp. (WGS) Fair Value 2026

WGS · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.4 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, GeneDx Holdings Corp. (WGS) trades at $86.33, versus a $15.24 median fair value across its 5 active models — 82.3% below the current price. QOC: 6.4/10. Value Trap Risk: 26/100 (LOW). 5/13 models active. Within that set, the Bayesian DCF component alone returns $3.58.

Key Facts

Ticker
WGS
Price
$86.33
Quality Score
6.4/10
Value Trap Risk
26/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is GeneDx Holdings Corp. (WGS) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, GeneDx Holdings Corp. (WGS) appears overvalued as of : the median of 5 independent fair value estimates is $15.24, 82.3% below the current price of $86.33. Estimates range from $3.07 to $45.03. WGS scores 6.4/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. WGS’s -82.3% gap is wider than that market norm, and the Diagnostics & Research sector median is -55.6%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy GeneDx Holdings Corp. Stock in 2026? →

What Fair Value Does Each Model Give WGS?

5 Intrinsic Value Models vs. Current Price ($86.33)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $3.58 -95.9%
Ensemble · Low Conviction
 $15.24 -82.3%
Unlock the Full Matrix

Access 3 additional models including Regime Cross-Sectional, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is WGS's Fair Value Range?

Spread across 5 independent models · $3.07 to $45.03

CirclFi's 5 active models place GeneDx Holdings Corp. (WGS) between $3.07 and $45.03 per share, a spread of 275% of the median. The median of that range — $15.24 — is the fair value CirclFi publishes for WGS, against a current price of $86.33.

Low · RCMH-DCFHigh · Regime Cross
$3.07median $15.24$45.03
Where the range comes from
Most bearish modelRCMH-DCF$3.07
Most bullish modelRegime Cross-Sectional$45.03
Model agreement0 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for WGS. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on WGS, not a CirclFi price target. How each model works →

What Is GeneDx Holdings Corp. (WGS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, GeneDx Holdings Corp.'s intrinsic value is estimated at $15.24, suggesting the stock is overvalued at its current price of $86.34. With 5 out of 5 models flagging downside (-82.3% vs price), the market may be pricing in unsustainable growth. Notably, Regime Cross sees the most upside at -47.8% (fair value: $45.03), while RCMH-DCF is the most conservative at -96.4% ($3.07). The spread between these extremes — +48.6% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About WGS?

5 of 13 models are currently active for WGS. All 5 active models suggest the stock trades above fair value. Taken together, their median fair value for WGS is $15.24 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $3.58 on its own, implying -95.9% downside from the current price. See which stocks rank higher →

How Does WGS Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, WGS ranks #32 by Quality of Company score. CirclFi's QOC score of 6.4/10 evaluates 32 fundamental signals. A score of 6.4 indicates above-average quality.

Within the Diagnostics & Research space, GeneDx Holdings Corp. competes in an environment where clinical trial success rate often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is WGS a Value Trap?

CirclFi's Value Trap algorithm assigns WGS a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for GeneDx Holdings Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, GeneDx Holdings Corp.'s fundamental quality profile registers 6.4/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +48.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every WGS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across WGS's 5 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy GeneDx Holdings Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

BNRBurning Rock Biotech LimitedQOC 6.5PSNLPersonalis, Inc.QOC 6.4MYGNMyriad Genetics, Inc.QOC 6.6AWHLAspira Women's Health Inc.QOC 6.4NEONeoGenomics, Inc.QOC 6.6BDSXBiodesix, Inc.QOC 6.3PRPHProPhase Labs, Inc.QOC 4.8MTDMettler-Toledo International Inc.QOC 8.7CSTLCastle Biosciences, Inc.QOC 7.4IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: BNR · PSNL · MYGN · AWHL · NEO · BDSX · PRPH · MTD · CSTL · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to WGS?

7 companies across all industries closest to WGS’s Quality of Company score of 6.4/10.

SJMThe J. M. Smucker CompanyQOC 6.4LCUTLifetime Brands, Inc.QOC 6.4ASYSAmtech Systems, Inc.QOC 6.4PTGXProtagonist Therapeutics, Inc.QOC 6.4ASPNAspen Aerogels, Inc.QOC 6.4TRAWTraws Pharma, Inc.QOC 6.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SJM · LCUT · ASYS · PTGX · ASPN · TRAW · NVDA

What Else Do Investors Ask About GeneDx Holdings Corp.’s Valuation?

What is GeneDx Holdings Corp.'s intrinsic value in 2026?

CirclFi puts GeneDx Holdings Corp. (WGS)'s intrinsic value at $15.24 — the median of 5 independent model estimates as of 2026-08-28, ranging from $3.07 to $45.03. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $3.58 on its own. The Quality of Company score is 6.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is WGS overvalued or undervalued right now?

At $86.33, 0 of 5 active models suggest WGS may be undervalued, while 5 indicate potential overvaluation. The median of all 5 fair value estimates is $15.24, 82.3% below the current price of $86.33 — a consensus view that WGS is overvalued. The assessment depends on which methodology best fits GeneDx Holdings Corp.'s business model in Diagnostics & Research.

What does a Quality of Company score of 6.4 mean for WGS?

GeneDx Holdings Corp.'s QOC of 6.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on WGS?

CirclFi analyzes WGS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on WGS?

Of the 5 models currently active on WGS, Regime Cross-Sectional is the most bullish at $45.03 per share, and RCMH-DCF is the most bearish at $3.07. CirclFi's published fair value for WGS is the median of that range, $15.24, not either extreme. The gap between the two ends equals 275% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is WGS a value trap in 2026?

GeneDx Holdings Corp.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, GeneDx Holdings Corp. (WGS) has a median fair value of $15.24 — 82.3% below the current price of $86.33 — as of 2026-08-28.” Source: circlfi.com/stock/WGS/ · Methodology
Primary sources for this WGS valuation
  • Financial statements: GeneDx Holdings Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0001818331) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for WGS as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on WGS.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for WGS Unlock All 5 — $39/mo